Currently, there is often a lack of suitable small-caliber graft vessels for treating cardiovascular diseases because of thrombosis and intimal hyperplasia. Tissue engineered vascular grafts (TEVGs) promise a potential solution to this issue. Acellular vascular matrix with good mechanical properties and biocompatibility is commonly used as a tissue engineered scaffold. In this study, acellular rat aortas were preloaded with heparin and hepatocyte growth factor (HGF) to fabricate small diameter TEVGs. In terms of the biomechanical properties, this scaffold was similar to native rat aortas. We implanted this scaffold into a rat abdominal aorta, and the acellular aorta with heparin only was used as control. The patency at 6 months of the two groups was 100%. At 1 month, a complete layer of endothelial cells could be seen on the surface of the vascular lumen of the scaffold with heparin and HGF. The results also showed that the intimal thickness was significantly reduced in the grafts coated with HGF compared to the control grafts. In conclusion, the small-diameter TEVGs constructed by acellular vascular scaffolds coated with heparin and HGF have a promising clinical application prospect.
Keywords: Tissue engineered vascular grafts; acellular vascular matrix; heparin; hepatocyte growth factor small-caliber graft.